Case report: repair of traumatic oronasal fistula using hydroxyapatite cement: a preliminary case report.
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
M Mount
Publications and source records attributed to M Mount.
A novel variant of the human blood group K1 antigen.
A discrepancy in duplicate anti-K1 typing in a parentage case led to the discovery of an unusual K1 blood group antigen. Red blood cells from the propositus (JC) express a rare variant of the K1 antigen that is detectable by only 8 of 72 sera containing anti-K1. Absorption and elution studies using reactive anti-K1 confirmed the presence of a K1 antigen. Nonreactive anti-K1 was not absorbed by or eluted from JC's red blood cells. Red cells from 3 of the propositus's siblings also had the variant K1 antigen. The variant antigen exhibited qualitative as well as quantitative differences as compared to normal K1, and we have named it K1var.
Adult↗
Pulsed brachytherapy: the conditions for no significant loss of therapeutic ratio compared with traditional low dose rate brachytherapy.
Pulsed brachytherapy consists of using a stronger radiation source than for traditional low dose-rate brachytherapy, but giving a series of short exposures of 10 to 30 min in every hour, to approximately the same total dose in the same overall time as with the low dose-rate. Calculations based on the linear quadratic model, in which the beta x dose squared component only is assumed to be repairable, and at a monoexponential rate, show that there is no significant loss of therapeutic ratio, defined as tumor damage for a given level of late damage. Some loss of therapeutic ratio would in principle be expected when dose rates are increased, but, in the presently proposed applications, there are so many small pulses (fractions at medium or low dose-rate) that even though repair is not usually complete between them, the relative increase of late damage (in units proportional to log cell kill) is less than 10% more than the increase of tumor damage, except in unlikely conditions that we define. Although these calculations suggest that pulsed brachytherapy should be safe for pulse repetition frequencies up to about 2 hr, using dose rates not exceeding about 3 Gy/hr, we discuss the radiobiological reservations and the limitations of such calculations.
Brachytherapy↗
A competitive enzyme-linked immunosorbent assay (ELISA) to detect retronecine and monocrotaline in vitro.
Antibodies to the nonesterified pyrrolizidine nucleus, retronecine (155 mol.wt), were produced in rabbits and detected using an avidin-biotin antibody ELISA. A competitive ELISA for the detection of retronecine and the cyclic diester monocrotaline was also developed using the antiserum produced against the hapten conjugate, retronecine-bovine serum albumin. Retronecine was obtained by hydrolysis of monocrotaline, succinylated and directly coupled to bovine serum albumin or ovalbumin. Antibodies to the pyrrolizidine nucleus, retronecine, can be detected within 5 min after the addition of substrate using the avidin-biotin ELISA. Competitive inhibition of antibodies to retronecine is obtained by the addition of known amounts (0-11.42 micrograms/microliters) of either the homologous antigen, retronecine, or the heterologous antigen, monocrotaline, however, retronecine acts as the better competitor.
Animals↗
Parentage testing using the serum protein plasminogen (PLG).
Isoelectric focusing of plasminogen (PLG) was tested on a Minnesota population of 2,187 white individuals and 451 paternity cases. A total of six different PLG allotypes were observed PLG*1, PLG*2, PLG*3, PLG*B, PLG*D and PLG*M. Observed gene frequencies predicted a probability P = 0.2 of excluding men who were falsely determined to be parents. The observed frequency of PLG exclusions among all exclusions detected in the study using a test battery of 14-16 genetic markers was similar to the expected value. PLG phenotyping proved to be a very useful genetic marker system in routine parentage testing.
Child↗